Mirzazade R. F.

THE ROLE OF PHYSIOTHERAPEUTIC FACTORS IN THE COMPLEX TREATMENT OF UVEITIS IN BEHCET’S DISEASE

---

Show/Download

About the author:

Mirzazade R. F.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The study included 22 patients (39 eyes) with uveitis in Behcet's disease. The patients were divided into three groups. Patients of all three groups received complex therapy with the appointment of general and local corticosteroids and immunosuppressants. Patients of the first group of 8 patients (12 eyes) additionally received endonasal electrophoresis with dexamethasone. In patients of the second group – 8 patients (16 eyes), a physiotherapeutic factor, a magnetic field, was used. In patients of the third group – 6 patients (11 eyes), therapy was performed without the use of physiotherapeutic factors. Complete resorption of edema and normalization of the thickness of the foveolar zone of the retina in the first group was observed in 8 out of 11 eyes (72.7%), in the second in 9 out of 13 eyes (69.2%) and in the third group in 5 out of 8 eyes (62.5%). Thus, the complex therapy of uveitis in Behcet's disease with the use of physiotherapeutic factors, compared with traditional treatment, has a more pronounced clinical effect. Endonasal electrophoresis with dexamethasone and a magnetic field are well tolerated by patients and can be used in the complex treatment of uveitis in Behcet's disease.

Tags:

Bibliography:

1. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behcet’s disease physiopathology: a contemporary review. Auto Immun Highlights. 2016;7(1):4. DOI: https://doi.org/10.1007/s13317-016-0074-7.
2. Onder M, Gurer MA. The multiple faces of Behcet’s disease and its aetiological factors. J. Eur. Acad. Dermatol. Venereol. 2000;15:126-136.
3. Hatemi G, Christensen R, Bang D, Bodaghi B, Celic AF, Fortune F, et al. 2018 update of the EULAR recommendation for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77:808-818. DOI: https://doi.org/10.1036/annrheumdis-2018-23225.
4. Alekberova ZS, Lisitsyna TA, Kudayev MT. Bolezn Behcheta. M.: Izdatelstvo Pero; 2022. 117 s.
5. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet’s disease: an analysis of 880 patients. Am. J. Ophthalmol. 2004;138:373-380.
6. Tursen U, Gürler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet’s disease. İnt. J. Dermatol. 2003;42:346-351.
7. van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behcet’s disease and treatment modalities. Semin in Arthritis Rheum. 2022;52:151956. DOI: 10.1016/j.semarthrit.2022.151956.
8. Alekberova ZS. Bolezn Behcheta: etnos i semeynaya aqreqasiya. Naucno-prakticheskaja revmatologiya. 2016;54(3):244-246.
9. Guedes MC, Borrego LM, Proença RD. Role of interleukin-17 in uveitis. Indian J Ophthalmol. 2016;64(9):628-634. DOI: https://doi.org/10.4103/0301-4738.194339.
10. Sertoglu E, Omma A, Yucel C, Colak S, Sandikcl SC, Ozgurtas T. The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Behçet’s disease. Scand J Clin Lab Invest. 2018;78(6):443-449. DOI: https://doi.org/10.1080/00365513.2018/1488179.
11. Kump II, Moeller KI, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA. Behcet’s disease: comparing 3 decades of response at the National Eye Institute. Can J Ophthalmol. 2008;43(4):468-472. DOI: https://doi.org/10.3129/i08-080.
12. Nussenblatt R. Uveitis in Behcet’s disease Int. Rev. Immunol. 1997;14:67-79.
13. Okada AA. Behcet’s disease: general concepts and recent advances. Current opinion in Ophthalmology. 2006;17(6):551-556.
14. Ksiaa I, Abroug N, Kechida M, Zina S, Jelliti B, Khochtali S, et al. Eye and Behcet’s disease. Journal Français d’Opthalmologie. 2019;42(4):el133-el146.
15. Marshall S.E. Behcet’s disease. Best Pract Res Clin Rheumatol 2004;18:291-311.
16. Nussenblatt RB, Whitcup SW. Uveitis. Fundamentals and clinical practice. 3rd ed. St. Louis: Mosby; 2004. 35 p.
17. Ozdal PÇ. Behcet’s Uveitis: Current Diagnostic and Therapeutic Approach. Turk J Ophthalmol. 2020;50(3):169-182. DOI: https://doi.org/10.4274/tjo.galenos.2019.60308.
18. Ozyazgan Y, Ucar D, Hatemi G, Yazici Y. Ocular Involvement of Behcet’s Syndrome: a Comprehensive Review. Clin Rev Allergy Immunol. 2015;49(3):298-306. DOI: https://doi.org/10.1007/s12016-014-8425-z.
19. Cunningham EJr, Tugal-Turkun I, Khairallah M, Okada A, Bodaghi B, Zeirhut M. Behcet’s Uveitis. Ocul Immunol Inflamm. 2017;25(1):2-6. DOI: https://doi.org/10.1080/09273948.2017.1279840.
20. Tugal-Tutkun J, Ona S, Altan-Yaycioglu R, Altunbas HH, Urgahcioglu M. Uveitis in Behcet’s disease: analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-380. DOI: https://doi.org/10.1016/j.ajo200403022.
21. Karadag O, Bolek EC. Management of Behcet’s syndrome. Rheumatology (Oxford). 2020;59(3):117. DOI: 10.1093/rheumatology/keaa086.
22. Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149(4):550-561.e10. DOI: 10.1016/j.ajo.2009.11.019.
23. Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Exp. opinion on Pharmacotherapy. 2009;10(15):2511-2525.
24. Ulashik VS. Obshaya fizioterapiya. Minsk: Knijnyi dom; 2008. 511 s.
25. Larina LA, Maychuk YuF. Magnitoforez Vitasika v lechenii pervichnoy reshetchatoy distrofii roqovitsi. Vestnik oftalmologii. 1998;6:23-25.
26. Korchazhkina NB, Drakon AK. Fizicheskaya i reabilitatsionnaya meditsina. M.: GEOTAR-Media; 2020. Glava 26, Zabolevanniya glaz. s. 518-524.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 4, 175, 425-432 pages, index UDC 617.723-002(075.8); 615.8

DOI:

10.29254/2077-4214-2024-4-175-425-432